Multicomponent Assembly Strategies for the Synthesis of Diverse Tetrahydroisoquinoline Scaffolds

Brett A. Granger, **Kyosuke Kaneda**, and **Stephen F. Martin**[*]

Department of Chemistry and Biochemistry, The Texas Institute for Drug and Diagnostic Development, The University of Texas at Austin, Austin, Texas 78712, United States

Abstract

Several novel multicomponent assembly processes have been developed for the rapid and efficient assembly of various heterocyclic scaffolds bearing a tetrahydroisoquinoline core, each of which allows for facile derivatization to access a diverse array of compounds. This work led to the serendipitous discovery of a new method for the synthesis of a fused quinazolone ring system, which was applied to a one-step total synthesis of the quinazolinocarboline alkaloid rutaecarpine.

The identification of potent and selective modulators of biological pathways is a key step in studying fundamental biology and discovering drug leads. Efforts to facilitate access to such compounds have fueled the development of several approaches for the generation of small molecule libraries.[1] Collections of small molecules containing privileged scaffolds, which are skeletal frameworks that bind to multiple receptors and display a wide range of biological activities,[2,3] often exhibit relatively high hit rates in screening assays. Initial hits can then be modified by introducing potency and selectivity enhancing substituents to give derivatives that exhibit favorable physiochemical properties.

We recently reported the design and development of a novel strategy for diversity-oriented synthesis (DOS) that featured a Mannich-type multicomponent assembly process (MCAP), followed by various cyclization reactions that were enabled by selective functional group pairing to construct substituted heterocyclic ring systems.[4–6] This approach has been extended to the synthesis and diversification of compounds based on the benzodiazepine, tetrahydropyridine, and aryl piperidine scaffolds.[7–9] We now report a further expansion of this approach for DOS and the development of several MCAPs that provide ready access to various privileged structures fused to a tetrahydroisoquinoline core, which itself is found in molecules that exhibit a wide array of biological activities, including antihypertensive,[10] anti-tumor,[11] and anti-malarial properties.[12]

sfmartin@mail.utexas.edu.

We chose the readily available 7-bromodihydro-isoquinoline (**1**) [13] as the common input for these MCAPs, because it allows for preparation of various derivatives via cross-coupling reactions with the aryl bromide moiety (Scheme 1). Inasmuch as compounds incorporating the highlighted tricyclic ring system in **7** are known to be potent α^2-adrenoceptor antagonists,[14] we sought to develop an efficient entry to this ring system.

Accordingly, treatment of **1** with *trans*-crotonyl chloride and silyl enol ether **2** in the presence of a catalytic amount of TMSOTf provided the aldehyde **3**, which upon condensation with *N*-methylhydroxylamine gave an intermediate nitrone that underwent facile 1,3-dipolar cycloaddition to provide isoxazolidine **4** in 66% yield from **1**; no other stereoisomers were isolated. The relative stereochemistry in **4** was unambiguously determined by single crystal x-ray analysis. Notably, **4** is easily prepared on a multi-gram scale without column chromatography. Subsequent reduction of the lactam moiety in **4**, followed by a Suzuki cross-coupling provided the biaryl isoxazolidine **6**. Upon treatment with nickel boride, **6** underwent *N,O*-bond cleavage to give the secondary amine **7** in 90% yield.[15] The amino group in **7** is an obvious point for further diversification as illustrated by its reaction with 2-furoyl chloride in the presence of triethylamine to furnish amide **8** in 77% yield.

We also wanted to explore methods for elaborating heterocyclic rings directly onto the parent dihydroisoquinoline **1**, and it occurred to us that appending a 1,4-diazepine-2,5-dione ring might be of considerable use. For example, *N,N′*-diphenethyl-1,4-diazepine-2,5-diones (highlighted portion of **12**) are of interest as inhibitors of the UCB13-UEV enzyme complex and hence may be useful as anti-tumor agents.[16] Since **12** represents a novel, constrained analog of these systems, we set to the task of preparing such compounds via our MCAP/ cyclization strategy. In the event, reaction of **1** with silyl ketene acetal **9** and chloroacetyl chloride in the presence of a catalytic amount of TMSOTf at −78 °C provided amide **10** in 89% yield (Scheme 2). When **10** was heated with primary alkyl amines in the presence of Hünig's base in CH_3CN the corresponding *N*-alkyl 1,4-diazepine-2,5-diones were obtained. For example, reaction of **10** with **11** provided **12** in 69% yield. Buchwald-Hartwig cross-coupling of **12** with morpholine (**13**) gave amine **14** in 72% yield.

The molecular framework embodied in **15** and **16** (6,7-dihydropyrimido[6,1-*a*]isoquinoline-2,4(3*H*,11*bH*)-dione) is present in compounds that exhibit hypotensive and diuretic effects.[17] We were thus were intrigued by the possibility that we might exploit an MCAP/cyclization sequence to access this ring system by a route that would be more expedient than those previously reported.[17a,18] Indeed, sequential treatment of **1** with TMSOTf, the silyl ketene acetal **9** and phenyl isocyanate provided **15** in 63% yield (Scheme 3). Because an isocyanate is implemented as the electrophilic component, this series of reactions represents a significant expansion of our MCAP chemistry to give products containing urea functionality. Preliminary studies using isothiocyanates as electrophilic inputs have not been as successful. Compound **15** was further elaborated via a Suzuki cross-coupling to give the aryl substituted tricyclic scaffold **16** in 92% yield.

The 1,5-benzodiazepin-2-one framework is present in many compounds that bind to multiple targets including the interleukin-1β converting enzyme (ICE)[19] and voltage-gated potassium channels.[20] More specifically, the triazolo 1,5-benzodiazepin-2-one scaffold, highlighted in **17** and **18**, is present in compounds reported to inhibit serine protease[21] and to bind to the benzodiazepine receptor.[22] Toward incorporating this ring system in fused isoquinolines, **1** was first allowed to react with either zinc phenylacetylide or ethynylmagnesium bromide in the presence of TMSOTf (Scheme 4). The intermediate adducts were then trapped with *o*-azidobenzoyl chloride, and upon warming to room temperature, the amide thus produced readily underwent a dipolar cycloaddition to furnish

the novel triazolo 1,5-benzodiazepin-2-ones **17** and **18** in 80% and 93% yields, respectively. Subsequent Buchwald-Hartwig or Suzuki cross-coupling reactions generated derivatives **21** and **22**.

During initial experiments that were directed toward developing the sequence outlined in Scheme 4, we discovered that acylation of dihydroisoquinoline **23** with *o*-azidobenzoyl chloride at room temperature, followed by addition of ethynylmagnesium bromide did not give the expected amide **26**; the benzaldehyde **24** and the quinazolone **25** were obtained instead (Scheme 5). Although **25** was isolated as a minor product, its formation suggested that we had serendipitously uncovered a new entry to quinazolones, a heterocyclic ring system present in a variety of pharmaceuticals and biologically active natural products.[3a,23]

After some optimization, we found that treatment of **1** with *o*-azidobenzoyl chloride in 1,2-dichloroethane under reflux provided quinazolone **27** in 62% yield (Scheme 6); no aldehyde was observed in the ^{1}H NMR spectrum of the crude reaction mixture. To the best of our knowledge, this represents the first example of an intramolecular cyclization of an organic azide onto a putative *N*-acyliminium ion to form a quinazolone.[24] Subsequent Suzuki cross-coupling of **27** provided the biaryl quinazolone **28** in 94% yield.

In order to showcase the utility of this novel route to quinazolones, we applied it to a one-step synthesis of the quinazolinocarboline alkaloid rutaecarpine (**30**). Rutaecarpine was isolated from the dried, unripe fruit of *Evodia Rutaecarpa* and displays various biological activities including being a potent and selective inhibitor of cytochrome P450 in human liver microsomes.[25,26] Simply treating dihydro-β-carboline hydrochloride (**29**)[27] with *o*-azidobenzoyl chloride in the presence of Hünig's base in dichloromethane delivered rutaecarpine (**30**) in 58% yield (Scheme 7).[24a,28]

In summary, we have developed several new MCAPs for the rapid synthesis of complex heterocyclic scaffolds in which tetrahydroisoquinolines are fused to 1,4-diazepine-2,5-dione, dihydropyrimidine-2,4-dione, 1,5-benzodiazepin-2-one, and quinazolone rings. These heterocycles bear functionality that may be further exploited in a variety of cross-coupling reactions to generate small compound libraries for submission to the NIH Molecular Libraries Small Molecule Repository (MLSMR). An important feature of this approach to DOS is that the members of these libraries typically have clogP values in the approximate range of 3.0–4.5; these compounds thus have excellent promise as potential leads. We also discovered a novel method to form fused quinazolone rings and have applied this discovery to a one-step synthesis of the quinazolinocarboline alkaloid rutaecarpine. Significantly, these novel reaction sequences can be applied to other imines, including those that are generated *in situ* by four-component assembly processes we have previously reported.[6–9] Further applications of this and related approaches to the syntheses of unique compound libraries are in progress, and the results of these investigations will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. (a) Brenner S, Lerner RA. Proc Natl Acad Sci USA. 1992; 89:5381–5383. [PubMed: 1608946] (b) Njardarson JT, Gaul C, Shan D, Huang X-Y, Danishefsky SJ. J Am Chem Soc. 2004; 126:1038–1040. [PubMed: 14746469] (c) Kaiser M, Wetzel S, Kumar K, Waldmann H. Cell Mol Life Sci. 2008; 65:1186–1201. [PubMed: 18193390] (d) Schreiber SL. Science. 2000; 287:1964–1969. [PubMed: 10720315]

2. Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PS, Chang RSL, Lotti VJ, Cerino DJ, Chen TB, Kling PJ, Kunkel KA, Springer JP, Hirshfield J. J Med Chem. 1988; 31:2235–2246. [PubMed: 2848124]

3. For leading references to privileged substructures, see: (a) Welsch ME, Snyder SA, Stockwell BR. Curr Opin Chem Biol. 2010; 14:347–361. [PubMed: 20303320] (b) DeSimone RW, Currie KS, Mitchell SA, Darrow JW, Pippin DA. Comb Chem High Throughput Screening. 2004; 7:473–493. (c) Horton DA, Bourne GT, Smythe ML. Chem Rev. 2003; 103:893–930. [PubMed: 12630855] (d) Constantino L, Barlocco D. Curr Med Chem. 2006; 13:65–85. [PubMed: 16457640]

4. For the first example of this process, see: Martin SF, Benage B, Hunter JE. J Am Chem Soc. 1988; 110:5925–5927.

5. For a review of such strategies, see: Sunderhaus JD, Martin SF. Chem-Eur J. 2009; 15:1300–1308.

6. (a) Sunderhaus JD, Dockendorff C, Martin SF. Org Lett. 2007; 9:4223–4226. [PubMed: 17887692] (b) Sunderhaus JD, Dockendorff C, Martin SF. Tetrahedron. 2009; 65:6454–6469. [PubMed: 20625454]

7. Donald JR, Martin SF. Org Lett. 2011; 13:852–855. [PubMed: 21275426]

8. Sahn JJ, Su JY, Martin SF. Org Lett. 2011; 13:2590–2593. [PubMed: 21513290]

9. Hardy S, Martin SF. Org Lett. 2011; 13:3102–3105. [PubMed: 21598984]

10. Gavras I, Vlahakos D, Melby JC, Gavras H. J Clin Pharm. 1984; 24:343–350.

11. Asaoka T, Yazawa K, Mikami Y, Takahashi K. J Antibiot. 1982; 35:1708–1710. [PubMed: 7166536]

12. Francois, G.; Bringmann, G.; Phillipson, JD.; Boyd, MR.; Assi, LA.; Schneider, C.; Timperman, G. U S Patent No. 5,639,761. 1994.

13. (a) Worrall DE. Org Synth. 1929; 9:66.(b) Schumacher RW, Davidson BS. Tetrahedron. 1999; 55:935–942.(c) Mjalli, AMM.; Gohimmukkula, DR.; Tyagi, S. U S Patent No. 7,208,601. 2005.

14. VanDyke JW Jr, Havera HJ, Johnson RD. J Med Chem. 1971; 15:91–93.

15. Jones AD, Knight DW, Thornton SR. J Chem Soc, Perkin Trans 1. 1999:3337–3344.

16. Okatsu, TT.; Sigmund, JS.; Peypoch, AM.; Ortiz, AR.; Pérez De Rozas, GS.; Masip, IM.; Fernández, AM.; Ruiz, DG.; León, AM. PCT Int Appl WO 2008009758. 2008. p. A1

17. (a) Kaneko, H.; Nagatsuka, T. Jpn Kokai Tokkyo Koho JP. 45009467. 1971. (b) Lombardino, JG.; McLaMore, WM.; Laubach, GD. U S Patent No. 3,021,331. 1962.

18. Angelov PA, Ivanov II, Venkov AP. Molecules. 2004; 9:694–704. [PubMed: 18007470]

19. Batchelor, MJ.; Bebbington, D.; Bemis, GW.; Fridman, WH.; Gillespie, RJ.; Golec, JMC.; Gu, Y.; Lauffer, DJ.; Livingston, DJ.; Matharu, SS.; Mullican, MD.; Murcko, MA.; Murdoch, R.; Nyce, PL.; Robidoux, ALC.; Wannamaker, MW.; Wilson, KY.; Zelle, RE. U S Patent No. 6,008,217. 1999.

20. Clareman, DA.; Liverton, N.; Selnick, GG.; Smith, GR. U S Patent No. 5,726,171. 1998.

21. Mohapatra DK, Maity PK, Shabab M, Khan MI. Bioorg Med Chem Lett. 2009; 19:5241–5245. [PubMed: 19648009]

22. Bertelli L, Biagi G, Giorgi I, Livi O, Manera C, Scartoni V, Martini C, Giannaccini G, Trincavelli L, Barili PL. Farmaco. 1998; 53:305–311. [PubMed: 9658589]

23. (a) Hughes AN, Rafi I, Griffin MJ, Calvert AH, Newell DR, Calvete JA, Johnston A, Clendeninn N, Body AV. Clin Cancer Res. 1999; 5:111–118. [PubMed: 9918208] (b) López-Gresa MP, González MC, Primo J, Moya P, Romero V, Estornell E. J Antibiot. 2005; 58:416–419. [PubMed: 16156520]

24. For other methods of preparation, see: (a) Eguchi S, Takeuchi H, Matsushita Y. Heterocycles. 1992; 33:153–156.(b) Wagner EC. J Org Chem. 1940; 5:133–141.(c) Grout RJ, Partridge MW. J Chem Soc. 1960:3551–3557.

25. Asahina Y, Kashiwaki K. J Pharm Soc Jpn. 1915:1293.

26. Ueng Y-F, Jan W-C, Lin L-C, Chen T-L, Guengerich FP, Chen C-F. Drug Met Disp. 2002; 30:349–353.

27. Späth E, Lederer E. Ber Dtsch Chem Ges. 1930; 63:2102–2111.

28. For selected synthesis of rutaecarpine, see: (a) Asahina Y, Manske RHF, Robinson R. J Chem Soc. 1927:1708–1710.(b) Kametani T, Higa T, Von Loc C, Ihara M, Koizumi M, Fukumoto K. J Am Chem Soc. 1976; 98:6186–6188.(c) Bergman T, Bergman S. J Org Chem. 1985; 50:1246–1255.(d) Zhang C, Kanta De C, Mal R, Seidel D. J Am Chem Soc. 2008; 130:416–417. [PubMed: 18081292] (e) Kamal A, Reddy MK, Reddy TS, Santos LS, Shankaraiah N. Synlett. 2011; 1:61–64.

**Scheme 1.**
Synthesis and Diversification of **7**

Scheme 2.
Synthesis of 1,4-Diazepine-2,5-diones

Scheme 3.
Synthesis of Dihydropyrimidine-2,4-diones

Scheme 4.
Synthesis of Triazolo 1,5-Benzodiazepin-2-ones

Scheme 5.
Formation of Quinazolone **25** as a Minor Side Product

Scheme 6.
Synthesis of Quinazolones **27** and **28**

Scheme 7.
Total Synthesis of Rutaecarpine (**30**)